Showing results (391-400 of 462) with videos related to

Sort By:
Pageof 47
Diagnostic Pathology|September 18, 2015
Differential expression of Mediator complex subunit MED15 in testicular germ cell tumorsNiklas Klümper, Isabella Syring, Anne Offermann, et al.
Journal of Cellular and Molecular Medicine|January 15, 2021
The pioneer and differentiation factor FOXA2 is a key driver of yolk-sac tumour formation and a new biomarker for paediatric and adult yolk-sac tumoursWasco Wruck, Felix Bremmer, Mara Kotthoff, et al.
American Journal of Human Genetics|December 19, 2003
Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more senseAnnemieke Aartsma-Rus, Anneke A M Janson, Wendy E Kaman, et al.
Oral Oncology|September 2, 2011
Prognostic value of DNA ploidy status in patients with oral leukoplakiaJantine F Bremmer, Ruud H Brakenhoff, Mark A M Broeckaert, et al.
The Journal of Pathology. Clinical Research|October 14, 2021
Quantitative proteomics identifies biomarkers to distinguish pulmonary from head and neck squamous cell carcinomas by immunohistochemistryAnnika Richter, Alexander Fichtner, Jasmin Joost, et al.
Gene Therapy|July 2, 2004
Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cellsA Aartsma-Rus, W E Kaman, M Bremmer-Bout, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|July 24, 2009
Late-life depression, cortisol, and the metabolic syndromeNicole Vogelzangs, Aartjan T F Beekman, Miranda G Dik, et al.
European Journal of Human Genetics : EJHG|October 20, 2000
Dystrophin nonsense mutation induces different levels of exon 29 skipping and leads to variable phenotypes within one BMD familyI B Ginjaar, A L Kneppers, J D v d Meulen, et al.
Human Molecular Genetics|April 2, 2003
Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patientsAnnemieke Aartsma-Rus, Anneke A M Janson, Wendy E Kaman, et al.
Pageof 47